Work

Abstract P1-04-01: Significance of circulating tumor cells in metastatic triple negative breast cancer: Results of an open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 tigatuzumab (TBCRC 019)

Year: 2013

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/0008-5472.sabcs13-p1-04-01

Authors: C Paoletti, Y Li, MC Muñiz, KM Kidwell, K Aung, DG Thomas, ME Brown, V Abramson, WJ Irvin, NU Lin, M Liu, R Nanda, J Nangia, AM Storniolo, TA Traina, C Vaklavas, CH Van Poznak, AC Wolff, A Forero, DF Hayes

Institutions: Mayo Clinic, Memorial Sloan Kettering Cancer Center, Baylor College of Medicine, University of Michigan, University of Alabama at Birmingham, University of Chicago, Dana-Farber Cancer Institute, Sidney Kimmel Comprehensive Cancer Center, UAB Medicine, U-M Rogel Cancer Center

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2027818296

Cites:

Cited by:

Related to: 10